Ketamine KETTLE trial: a single infusion to ease anorexia distress

NCT ID NCT06736769

ENROLLING_BY_INVITATION Symptom relief Sponsor: Amanda Downey, MD Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial tests a single intravenous dose of ketamine in 20 hospitalized teens and young adults with anorexia nervosa or atypical anorexia. Researchers want to see if ketamine helps the brain become more flexible, making it easier to learn new, positive associations with food and reducing distress during hospitalization.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ketamine
What this could lead to: If it works, this could point toward a new way to help hospitalized teens with anorexia feel less distressed and more flexible around food.
What could go wrong: This is a very small, early-phase trial with only 20 people and a single dose. It may not show clear benefits, and ketamine can cause side effects like dizziness or dissociation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANOREXIA NERVOSA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Anorexia anorexia nervosa anxiety disorder Depression Feeding and Eating Disorders

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANOREXIA NERVOSA ATYPICAL ANOREXIA NERVOSA

Contacts and locations

Locations

University of California, San Francisco

San Francisco, California, 94158, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.